Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study on the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutations

NCT07231068 is registered in ClinicalTrials.gov with Henan Genuine Biotech Co., Ltd. as lead sponsor.

NCT NCT07231068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07231068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study on the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutations
Lead sponsor
Henan Genuine Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 31, 2022
Completion date
December 31, 2029
Enrollment
153 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer